First FDA approved immunotherapy for Merkel cell carcinoma implemented in locations worldwide

November 13, 2017

Authorization for BAVENCIO® (avelumab) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC) has been granted in several locations worldwide.

Updates on avelumab approvals:

  • United States — March 23, 2017
  • Switzerland — September 5, 2017
  • European Union (+ Norway, Liechtenstein and Iceland) — September 21, 2017
  • Japan — September 27, 2017